Amneal Pharmaceuticals (AMRX) Cash from Investing Activities (2017 - 2026)

Amneal Pharmaceuticals' Cash from Investing Activities history runs 10 years deep, the most recent figure standing at -$21.7 million for Q1 2026.

• In Q1 2026, Cash from Investing Activities fell 21.98% year-over-year to -$21.7 million; the TTM figure through Mar 2026 stood at -$116.2 million (down 90.34% YoY), while the FY2025 annual figure was -$112.3 million, down 78.21% from the prior year.
• Cash from Investing Activities for Q1 2026 stood at -$21.7 million, up from -$45.5 million in the prior quarter.
• The five-year high for Cash from Investing Activities was -$6.5 million in Q2 2024, with the low at -$97.4 million in Q1 2022.
• The 5-year median for Cash from Investing Activities is -$19.8 million (2024), against an average of -$25.9 million.
• The sharpest annual moves came in 2022 and 2023: Cash from Investing Activities sank 667.31% in 2022, then soared 87.95% in 2023.
• Amneal Pharmaceuticals' Cash from Investing Activities stood at -$11.5 million in 2022, then slumped by 176.4% to -$31.7 million in 2023, then surged by 49.33% to -$16.1 million in 2024, then sank by 183.04% to -$45.5 million in 2025, then jumped by 52.24% to -$21.7 million in 2026.
• Business Quant data shows AMRX's Cash from Investing Activities at -$21.7 million in Q1 2026, -$45.5 million in Q4 2025, and -$22.5 million in Q3 2025.